PhRMA "Re-Repositioning"? Working Group Studying Rx Affordability Ahead Of Annual Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer exec Katen is overseeing group studying access and affordability issues. Association hopes to build on spirit of "repositioning" work that led to marketing guidelines in 2002.
You may also be interested in...
PhRMA Taps Former Hill Staffer Easton To Head Affordability, Access Group
Michelle Easton will oversee advocacy efforts on a wide range of programs and will work closely with health care partners in the newly created role of VP-group on affordability & access. She was a legislative assistant for former Rep. (now PhRMA CEO) Tauzin before working in former Sen. Breaux’s office for eight years.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.